LYSward™: A pH-Dependent Antibody Platform for ADCs

DCB's LYSward™ platform utilizes pH-dependent antigen binding to enhance payload release and improve the anti-tumor activity of ADCs. This innovative approach may help reduce drug resistance and enable the development of next-generation ADC therapies.

Industrial Applications:

The LYSward™ platform can be applied to the development of next-generation antibody-drug conjugates (ADCs), enhancing intracellular payload release and improving anti-tumor efficacy while reducing the risk of resistance caused by antigen loss. This technology can be used to develop more effective ADC therapeutics as well as optimize existing ADC products, increasing their clinical value and market competitiveness. In addition, LYSward™ offers strong potential for technology licensing and industry partnerships, making it a promising platform for next-generation ADC development.

Development Center for Biotechnology

Development Center for Biotechnology (DCB), established in 1984, is a nonprofit institute dedicated to advancing Taiwan’s biotech industry, located at the National Biotechnology Research Park. With nearly 400 professionals, DCB focuses on preclinical and translational research, supports new drug commercialization, and offers R&D, technology licensing, and contract services. Leveraging strong scientific capabilities and global collaborations, DCB strives to be the industry’s best partner and to enhance Taiwan’s international competitiveness.

Contact Information

Name：YU-HSUN LO

Tel：02-7700-3800#5406

Address：No.107, Ln. 130, Sec. 1, Academia Rd., Nangang Dist., Taipei City 11571, Taiwan, R.O.C.

Additional Information

Pavilion：Innovation Economy Pavilion Precision Health ID07

Exhibiting Entity：Department of Industrial Technology,MOEA

Application Category：Biotechnology and Medicine

Exhibition